Suppr超能文献

1例盘状红斑狼疮继发白癜风患者接受托法替布治疗。

A case of vitiligo secondary to discoid lupus erythematosus treated with tofacitinib.

作者信息

Jin Shiyu, Wang Shiwen, Jin Sha, Tang Chenyu, Wang Ping

机构信息

Department of Dermatology, Hangzhou Third People's Hospital, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.

Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.

出版信息

Medicine (Baltimore). 2025 Jun 27;104(26):e43118. doi: 10.1097/MD.0000000000043118.

Abstract

RATIONALE

Vitiligo is a common autoimmune disorder characterized by melanocyte destruction, leading to depigmented patches. It is often associated with other autoimmune diseases, including thyroid disease and systemic lupus erythematosus. Discoid lupus erythematosus (DLE) is a prevalent form of cutaneous lupus, and both conditions involve the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. However, the co-occurrence of vitiligo secondary to DLE is rare, and therapeutic approaches remain challenging. This case highlights the potential role of tofacitinib, a JAK inhibitor, in treating this dual pathology.

PATIENT CONCERNS

A 49-year-old male presented with erythematous lesions on his hands, ears, and forearms, without systemic symptoms. Histopathology confirmed DLE. Despite treatment with hydroxychloroquine and tacrolimus, new white spots developed within the DLE lesions, indicating progressive vitiligo secondary to DLE.

DIAGNOSES

Histopathology and clinical findings, along with skin computed tomography, revealed both DLE and progressive vitiligo. The diagnosis was confirmed based on the presence of depigmented lesions within existing DLE areas.

INTERVENTIONS

Tofacitinib (5 mg twice daily) was initiated alongside hydroxychloroquine. The patient was monitored over a 12-month period.

OUTCOMES

After 1 year of continued tofacitinib treatment, the lesions continued to improve without adverse effects, demonstrating the drug's effectiveness in this complex case.

LESSONS

This case illustrates the successful use of tofacitinib in treating vitiligo secondary to DLE, emphasizing the therapeutic potential of JAK inhibition in overlapping autoimmune skin conditions. Further studies are warranted to validate its long-term safety and efficacy in such complex cases. This is a single case report with a short follow-up duration. Lack of immunologic profiling limits broader generalizability. Controlled studies are needed to confirm these findings.

摘要

理论依据

白癜风是一种常见的自身免疫性疾病,其特征为黑素细胞破坏,导致色素脱失斑。它常与其他自身免疫性疾病相关,包括甲状腺疾病和系统性红斑狼疮。盘状红斑狼疮(DLE)是皮肤型狼疮的一种常见形式,这两种疾病都涉及 Janus 激酶-信号转导子和转录激活子(JAK-STAT)信号通路。然而,继发于 DLE 的白癜风合并出现的情况很少见,治疗方法仍然具有挑战性。本病例突出了 JAK 抑制剂托法替布在治疗这种双重病理情况中的潜在作用。

患者情况

一名 49 岁男性双手、耳部和前臂出现红斑性病变,无全身症状。组织病理学确诊为 DLE。尽管使用羟氯喹和他克莫司进行了治疗,但 DLE 病变内出现了新的白斑,表明继发于 DLE 的进行性白癜风。

诊断

组织病理学和临床检查结果以及皮肤计算机断层扫描显示同时存在 DLE 和进行性白癜风。根据现有 DLE 区域内色素脱失病变的存在确诊。

干预措施

在继续使用羟氯喹的同时开始使用托法替布(每日两次,每次 5mg)。对患者进行了为期 12 个月的监测。

结果

持续使用托法替布治疗 1 年后,病变持续改善且无不良反应,证明该药物在这一复杂病例中的有效性。

经验教训

本病例说明了托法替布在治疗继发于 DLE 的白癜风方面的成功应用,强调了 JAK 抑制在重叠性自身免疫性皮肤病中的治疗潜力。有必要进行进一步研究以验证其在这类复杂病例中的长期安全性和有效性。这是一篇随访时间较短的单病例报告。缺乏免疫分析限制了更广泛的普遍性。需要进行对照研究来证实这些发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验